Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐BCRinhibitor setting: aUKwide analysis-Reference-Cited by-同舟云学术

Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐BCRinhibitor setting: aUKwide analysis

Published:2019-02-15 Issue:4 Volume:185 Page:656-669
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Eyre Toby A.¹^ORCID,Kirkwood Amy A.²,Gohill Sat³,Follows George⁴,Walewska Renata⁵,Walter Harriet⁶,Cross Matthew⁷,Forconi Francesco⁸,Shah Nimish⁹,Chasty Richard¹⁰,Hart Alistair¹¹,Broom Angus¹²,Marr Helen¹³,Patten Piers E. M.¹⁴,Dann Andy¹⁵,Arumainathan Arvind¹⁶,Munir Tal¹⁷,Shankara Paneesha¹⁸,Bloor Adrian¹⁹,Johnston Rosalynd²⁰,Orchard Kim²¹,Schuh Anna H.¹²²,Fox Christopher P.²³,

Affiliation:

1. Department of Haematology Churchill Hospital Oxford University Hospitals NHS Foundation Trust OxfordUK

2. Cancer Research UK & UCL Cancer Trials Centre UCL LondonUK

3. Department of Haematology University College London Hospitals LondonUK

4. Department of Haematology Addenbrooke's Hospital NHS Trust CambridgeUK

5. Department of Haematology Royal Bournemouth Hospital BournemouthUK

6. Department of Haematology Leicester Royal Infirmary LeicesterUK

7. Department of Haematology The Royal Marsden Hospital LondonUK

8. Haematology Department University Hospital Trust and Cancer Sciences Unit Cancer Research UK and National Institute for Health Research Experimental Cancer Medicine Centres Faculty of Medicine University of Southampton SouthamptonUK

9. Department of Haematology Norfolk and Norwich University Hospital National Health Service Trust Norwich UK

10. Department of Haematology University Hospitals of North Midlands NHS Trust Stoke‐on‐Trent UK

11. Department of Haematology Queen Elizabeth University Hospital GlasgowUK

12. Department of Haematology Western General Hospital EdinburghUK

13. Department of Haematology Freeman Hospital Newcastle on TyneUK

14. Department of Haematological Medicine Kings College Hospital LondonUK

15. Department of Haemato‐Oncology The Ipswich Hospital NHS Trust IpswichUK

16. Clatterbridge Cancer Centre NHS Foundation Trust LiverpoolUK

17. Department of Haematology St James's University Hospital LeedsUK

18. Department of Haematology Heartlands Hospital BirminghamUK

19. Department of Haematology The Christie Hospital NHS Trust ManchesterUK

20. Department of Haematology Royal Sussex County Hospital BrightonUK

21. Department of Haematology and Bone Marrow Transplantation University Hospital Southampton SouthamptonUK

22. Oxford Molecular Diagnostic Centre Department of Oncology University of Oxford John Radcliffe Hospital Oxford UK

23. Department of Haematology Nottingham University Hospitals NHS Trust Nottingham UK

Funder

Oxford NIHR Biomedical Research Centre

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15802

Reference21 articles.

1. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

2. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

3. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

4. Models and life‐tables regression;Cox D.R.;Journal of the Royal Statistics Society,1972

5. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of venetoclax in relapsed/refractory chronic lymphocytic leukemia in Russia routine clinical practice;Oncohematology;2024-09-01

2. Ready, AIM, stop: ibrutinib plus venetoclax in MCL;Blood;2024-08-22

3. Holding the therapy in CLLp53: mechanisms to achieve durable responses;Anti-Cancer Drugs;2024-08-09

4. Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed;Cancers;2024-05-25

5. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial;The Lancet Oncology;2024-04